Literature DB >> 20604722

Clinical significance of serum macrophage-colony stimulating factor (M-CSF) in esophageal cancer patients and its comparison with classical tumor markers.

Marta Łukaszewicz-Zajac1, Barbara Mroczko, Mirosław Kozłowski, Jacek Nikliński, Jerzy Laudański, Maciej Szmitkowski.   

Abstract

BACKGROUND: Hematopoietic growth factors (HGFs), such as macrophage-colony stimulating factor (M-CSF) are produced aberrantly in many malignancies. Esophageal cancer (EC) is characterized by late diagnosis, rapid progression and poor survival. The purpose of the present study was to determine the clinical usefulness of M-CSF in the diagnosis of EC and its histological type - squamous cell cancer of the esophagus (ESCC).
METHODS: The study included 80 patients with EC (54 with ESCC and 26 with adenocarcinoma of the esophagus) and 30 healthy subjects. The serum concentrations of M-CSF, carcinoembryonic antigen (CEA) and squamous cell cancer antigen (SCC-Ag) were determined using immunoenzyme assays. We defined the percentage of increased concentrations of proteins tested and the areas under the receiver-operating characteristics (ROC) curves.
RESULTS: In EC and ESCC patients, serum concentrations of M-CSF, CEA and SCC-Ag were significantly higher compared with healthy subjects. Concentrations of M-CSF in both groups analyzed (EC and ESCC) showed a tendency for increases with depth of tumor invasion, the presence of lymph node and distant metastases. The combined use of M-CSF with SCC-Ag increased their percentage of increased concentrations, and this value was higher than for classical tumor markers in both groups analyzed. The area under ROC curve for M-CSF was larger than for CEA in EC patients.
CONCLUSIONS: Our findings suggest the potential usefulness of serum M-CSF concentrations as a tumor marker for EC, especially in combination with SCC-Ag. However, the diagnostic value of this cytokine may be limited because of its non-specific nature.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20604722     DOI: 10.1515/CCLM.2010.274

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus).

Authors:  Marta Lukaszewicz-Zając; Barbara Mroczko; Mirosław Kozłowski; Jacek Nikliński; Jerzy Laudański; Maria Siewko; Maciej Szmitkowski
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

2.  Exploration of macrophage colony-stimulating factor as a new type of tumor marker.

Authors:  Ru Zhou; Yiming Zhou; Zongyou Chen
Journal:  Biomed Rep       Date:  2013-09-25

3.  Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma.

Authors:  Liu Yang; Qian Wu; Le Xu; Weijuan Zhang; Yu Zhu; Haiou Liu; Jiejie Xu; Jianxin Gu
Journal:  BMC Cancer       Date:  2015-02-18       Impact factor: 4.430

Review 4.  Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting.

Authors:  Tetiana Hourani; James A Holden; Wenyi Li; Jason C Lenzo; Sara Hadjigol; Neil M O'Brien-Simpson
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

5.  Tumor Lymphocyte Infiltration Is Correlated with a Favorable Tumor Regression Grade after Neoadjuvant Treatment for Esophageal Adenocarcinoma.

Authors:  Riad Haddad; Oran Zlotnik; Tal Goshen-Lago; Mattan Levi; Elena Brook; Baruch Brenner; Yulia Kundel; Irit Ben-Aharon; Hanoch Kashtan
Journal:  J Pers Med       Date:  2022-04-13

Review 6.  What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer?

Authors:  Rodrigo Nalio Ramos; Cristiano Jacob de Moraes; Bruna Zelante; José Alexandre M Barbuto
Journal:  Clin Dev Immunol       Date:  2013-05-22

7.  The Serum Concentrations of Chemokine CXCL12 and Its Specific Receptor CXCR4 in Patients with Esophageal Cancer.

Authors:  Marta Łukaszewicz-Zając; Barbara Mroczko; Mirosław Kozłowski; Maciej Szmitkowski
Journal:  Dis Markers       Date:  2016-03-03       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.